SCHEMBL2148569

SCHEMBL2148569

c1cc(-c2cc[nH]n2)ccn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.48
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
MAPK1 P28482 1/20 0.39
NOTUM Q6P988 1/20 0.39
PDPK1 O15530 1/20 0.37
AR P10275 2/20 0.36
NPC1 O15118 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
RAB9A P51151 1/20 0.36
GSK3B P49841 1/20 0.36
MKNK1 Q9BUB5 1/20 0.36
MKNK2 Q9HBH9 1/20 0.36
DDAH1 O94760 1/20 0.35
NOS1 P29475 1/20 0.35
TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16766999 0.85 LMNA (0.36) IDO1LMNAMAPTMAPK1NOTUM
SCHEMBL31111685 0.80 IDO1 (0.44) IDO1LMNAMAPTMAPK1NOTUM
SCHEMBL9438 0.78 CYP1A2 (0.48) IDO1MAPTMAPK1CYP1A2RAB9A
SCHEMBL31111956 0.77 IDO1 (0.45) IDO1LMNAMAPTMAPK1NOTUM
SCHEMBL28313237 0.77
Pyrimidine SCHEMBL28120108 0.77 CYP1A2 (0.40) IDO1NOTUMCYP1A2RAB9ANISCH
Ammonia Solution, Strong SCHEMBL29843017 0.76 CYP1A2 (0.47) IDO1MAPTMAPK1CYP1A2RAB9A
SCHEMBL31519384 0.76 CYP1A2 (0.47) IDO1MAPTMAPK1CYP1A2RAB9A
SCHEMBL30636164 0.76 CYP1A2 (0.47) IDO1MAPTMAPK1CYP1A2RAB9A
SCHEMBL842040 0.76 CYP1A2 (0.47) IDO1MAPTMAPK1CYP1A2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024123967-A1 SARM1 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS SENYA PHARMACEUTICALS, INC. (US) 2024-06-13 WO claimed
WO-2023004280-A1 SELECTIVE PYRAZOLE LRRK2 INHIBITORS AND METHODS FOR USE THEREOF THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2023-01-26 WO claimed
CN-115317489-A Application of BML-275 in preparation of dormant polyploid giant tumor cell inhibitor 南通大学附属医院 2022-11-11 CN claimed
CN-109251214-B Zinc complex and preparation method and application thereof 衡水学院 2020-12-08 CN claimed
CN-108997594-B Polyacid-based metal organic framework crystal material with polyacid as template 哈尔滨理工大学 2020-11-24 CN claimed
CN-105682461-B Pesticidal combination and relative method 美国陶氏益农公司 2019-06-14 CN claimed
CN-109251214-A A kind of Zn complex and its preparation method and application 衡水学院 2019-01-22 CN claimed
CN-108997594-A A kind of polyacid is the polyacid Base Metal organic frame crystalline material of template 哈尔滨理工大学 2018-12-14 CN claimed
EP-4720678-A1 SURVIVIN AS A BIOMARKER FOR PREDICTING THE RESPONSIVENESS OF CANCER TREATMENT Boehringer Ingelheim International GmbH (DE) 2026-04-08 EP disclosed
US-12486274-B2 Substituted pyrazolo-pyrimidines and uses thereof Verge Analytics, Inc. (US) 2025-12-02 US disclosed
US-20250288589-A1 PYRIDOPYRIMIDINES AND METHODS OF THEIR USE Kineta, Inc. 2025-09-18 US disclosed
US-12391690-B2 Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same LIGACHEM BIOSCIENCES INC. (KR) 2025-08-19 US disclosed
CN-115209952-B Substituted pyrazolopyrimidines and use thereof 维基分析有限公司 2025-05-30 CN disclosed
CN-119841847-A Cyclic 2-amino-3-cyanothiophenes and derivatives thereof for the treatment of cancer 勃林格殷格翰国际有限公司 2025-04-18 CN disclosed
WO-2002016380-A1 NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY BASILEA PHARMACEUTICA AG (CH) 2002-02-28 WO disclosed
EP-1142890-A1 AMINOPYRAZOLE DERIVATIVES TEIKOKU HORMONE MFG. CO., LTD. (JP) 2001-10-10 EP disclosed
CN-1049658-C Pyrazolo[4,3-c]pyridines, a process for their preparation and their use as serotonin reuptake inhibitors HOECHST MARION ROUSSEL INC (US) 2000-02-23 CN disclosed
CN-1099033-A Pyrazolo [4,3-c] pyridine, their preparation method and as the purposes of serotonin reuptake inhibitors HOECHST ROUSSEL PHARMA (US) 1995-02-22 CN disclosed
CN-85105299-A The preparation method of cephem compounds 1987-01-07 CN disclosed
EP-0160969-A2 Cephem compounds Takeda Chemical Industries, Ltd. (JP) 1985-11-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12486274-B2 Substituted pyrazolo-pyrimidines and uses thereof PIKFYVE, PIP4K2B, PIP4K2C IDO1 4336/4885LMNA 3896/4885MAPT 770/4885
US-12391690-B2 Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same ENPP2, PLA2G10, LPCAT1 IDO1 390/4885LMNA 4301/4885MAPT 2439/4885
US-20250288589-A1 PYRIDOPYRIMIDINES AND METHODS OF THEIR USE PNPO, DPYD, PYGB IDO1 2417/4885LMNA 1215/4885MAPT 227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.